PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced that Michael Gerard has been appointed general counsel this week.
“We are very pleased to welcome Mike to the executive team. His experience with a wide range of strategic legal and corporate matters within the life sciences industry will complement the management team as we advance clinical development for DSG3-CAART in our DesCAARTes™ trial, and further develop follow-on candidates from our deep pipeline of precision therapies for patients with B cell-mediated autoimmune diseases,” said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta. “In addition to his dynamic and highly relevant legal experience, Mike shares our vision, our values and our passion for the pursuit of cures for patients with autoimmune diseases.”
Mr. Gerard most recently served as Associate General Counsel at Spark Therapeutics, a member of the Roche Group. While at Spark, he supported the global gene therapy Manufacturing, Business Development, Technical Development, Supply Chain, Quality, Alliance Management, Real Estate, IT and Facilities teams. Prior to joining Spark, he worked in roles of increasing responsibility at Sandoz, a division of the Novartis Group, achieving the position of Executive Director, Associate General Counsel, BD&L, Strategy and Portfolio. Mr. Gerard also worked as Assistant General Counsel at Aramark. He began his legal career at K&L Gates LLP, later joining Morrison & Foerster LLP before assuming his roles as in-house counsel. Mr. Gerard holds a J.D. from Cornell Law School and received his B.A. in Political Science from the University of Michigan.
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.